Bristol-Myers Squibb (BMY) Tops Q1 EPS by 1c, Reaffirms Forecast; Plans IPO for Mead Johnson Nutritionals
More News related to BMY
- Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESC Highlights
- Analyst Reports for Bristol-Myers Squibb Company, Merck & Co. Inc., Idearc Inc., and Northwest Airlines Corporation
- Bristol-Myers (BMY) and Pfizer (PFE) Provide Update on Apixaban Clinical Development Program - Primary Endpoint Not Met
- Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program
- Pre-Open Movers 8/20: Novatel (NVTL) Sinks On Results/Guidance; Suntech (STP) Higher
Bristol-Myers Squibb Co. (NYSE: BMY) reports Q1 EPS of $0.42, 1 cents better than estimates. Revenues came in at $5.18 billion, versus the consensus of $5.12 billion.
Reaffirms forecast.
Announces Plan to File Initial Public Offering of Approximately 10% of Mead Johnson Nutritionals. [LJ]
Related Categories
EarningsGuidance
Hot List
IPOs
Stocks Mentioned
-0.30Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
